BioSpace News Archive

Spero Therapeutics, Inc. announced that on March 23, 2023, the Compensation Committee of Spero’s Board of Directors approved the grant of an aggregate of 95,000 restricted stock unit awards to four new employees under the Spero Therapeutics, Inc. 2019 Inducement Equity Incentive Plan, as amended, or the 2019 Inducement Plan.

NightHawk Biosciences, a fully-integrated biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, provided strategic, financial, and operational updates for the year ended December 31, 2022.

Kineta, Inc. announced financial results for the full-year ended December 31, 2022 and provided a corporate update.

Boca Raton, Florida--(Newsfile Corp. - March 31, 2023) - NovelStem International Corp. (OTC Pink: NSTM), a development-stage company focused on the stem cell-based technology platform developed by Israel-based NewStem Ltd., today filed its Form 10-K for the year ended December 31, 2022. NovelStem owns a 30.58% equity interest in NewStem Ltd.

Emmaus Life Sciences, Inc., a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, reported its results of operation for the year ended December 31, 2022 and an update on recent activities.

AgeX Therapeutics, Inc., a biotechnology company developing therapeutics for human aging and regeneration, reported its financial and operating results for fourth quarter and the full year ended December 31, 2022.

Arrowhead Pharmaceuticals, Inc. announced that as an inducement to entering into employment with the Company, on March 29, 2023, the Compensation Committee of the Company’s Board of Directors approved “inducement” grants to 31 new employees under Rule 5635 of the NASDAQ Listing Rules.

Adicet Bio, Inc., a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, announced it granted inducement awards on March 31, 2023.

Oncocyte Corporation, a precision diagnostics company, announced plans to file a Form 12b-25 with the U.S. Securities and Exchange Commission regarding its Annual Report on Form 10-K and reports preliminary financial results for the full year ended December 31, 2022.

Ainos, Inc., a diversified medtech company focused on the development of novel point-of-care testing, low-dose interferon therapeutics, and synthetic RNA-driven preventative medicine, announced its financial results for the fourth quarter and full year ended December 31, 2022.